BCM
EW icon

BBT Capital Management’s Edwards Lifesciences EW Stock Holding History

BBT Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,870
Closed -$238K – 42
2019
Q2 		$238K Buy
+3,870
New +$234K 0.28% 149

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BBT Capital Management's EW Position: Q3 2019 in Review

BBT Capital Management sold out of Edwards Lifesciences (EW) in Q3 2019, closing a stake of 3,870 shares — an estimated $238K sold.

BBT Capital Management first reported a position in EW in Q2 2019 and held it in 1 quarter. The position peaked at $238K in Q2 2019. 964 funds tracked by Wall St. Rank hold EW as of Q3 2019.

  • BBT Capital Management reported no remaining Edwards Lifesciences position as of Q3 2019 after selling out during the quarter.
  • BBT Capital Management sold 3,870 Edwards Lifesciences shares in Q3 2019, an estimated $238K.
  • BBT Capital Management first reported a position in Edwards Lifesciences in Q2 2019 and held it in 1 quarter.
  • BBT Capital Management's Edwards Lifesciences position peaked at $238K in Q2 2019.
  • 964 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2019.

Based on BBT Capital Management's 13F filing for Q3 2019.